A new finding in this trial is the superior duration of HEPLISAV to Engerix-B. Based on the results of intensive safety monitoring over 12 months, we have again demonstrated that HEPLISAV has a ...

“These results are truly exciting and demonstrate, in a large multicenter controlled trial, the impressive efficacy of Sci-B-Vac at a dose half that of other hepatitis B vaccines,” said one of the ...

Administration Administer Engerix-B by intramuscular injection. The preferred administration site is the anterolateral aspect of the thigh for infants younger than 1 year and the deltoid muscle in ...

After getting go-aheads from multiple regulatory agencies, VBI Vaccines started phase 3 testing of its hepatitis B vaccine Sci-B-Vac against its future rival, GSK's Engerix-B, aiming to file for ...

(Reuters) - VBI Vaccines Inc said on Monday a late-stage study was unsuccessful in showing two doses of its hepatitis B vaccine were as effective as three doses of an older vaccine from ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today ...

A CDC advisory committee on Wednesday strengthened its recommendations for hepatitis B vaccination, and that's likely to flood the market with people seeking shots. Among the three approved vaccines, ...

There was no higher risk of heart attack for recipients of the two-dose hepatitis B cytosine phosphoguanine adjuvant vaccine (Heplisav-B) compared to the three-dose hepatitis B vaccine with an ...

In receiving its first-ever FDA approval for a Hepatitis B virus (HBV) vaccine indicated for adults, VBI Vaccines has set its sights on disrupting a market it expects could double—a market currently ...

VBI Vaccines Inc said on Monday a late-stage study testing its hepatitis B vaccine against GlaxoSmithKline's Engerix-B met its main goals. The trial administered VBI's Sci-B-Vac at a 10 microgram dose ...